These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 30360706)
1. Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia. Stefanutti C; Zenti MG Curr Pharm Des; 2018; 24(31):3634-3637. PubMed ID: 30360706 [TBL] [Abstract][Full Text] [Related]
2. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?]. Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875 [TBL] [Abstract][Full Text] [Related]
3. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985 [TBL] [Abstract][Full Text] [Related]
13. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy. Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977 [TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389 [TBL] [Abstract][Full Text] [Related]
15. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604 [TBL] [Abstract][Full Text] [Related]
16. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Arca M Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383 [TBL] [Abstract][Full Text] [Related]
17. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
18. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
19. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076 [TBL] [Abstract][Full Text] [Related]
20. PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy. Toscano A; Cinquegrani M; Scuruchi M; Di Pino A; Piro S; Ferrara V; Morace C; Lo Gullo A; Imbalzano E; Purrello F; Squadrito G; Scicali R; Mandraffino G Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]